Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Inobrodib |
| Trade Name | |
| Synonyms | CCS-1477|CCS 1477|CCS1477 |
| Drug Descriptions |
Inobrodib (CCS-1477) binds to and inhibits p300 (EP300) and CBP (CREBBP) and inhibits NRF2-dependent transcription, potentially resulting in increased anti-tumor immune response, increased cell cycle arrest, and inhibition of tumor growth (PMID: 33431496, PMID: 39266679, PMID: 40127850, PMID: 39885312). |
| DrugClasses | CBP/p300 inhibitor 13 |
| CAS Registry Number | 2222941-37-7 |
| NCIT ID | C160195 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Abiraterone + Inobrodib | Abiraterone Inobrodib | 0 | 1 |
| Atezolizumab + Inobrodib | Atezolizumab Inobrodib | 0 | 1 |
| Darolutamide + Inobrodib | Darolutamide Inobrodib | 0 | 1 |
| Dexamethasone + Inobrodib + Pomalidomide | Dexamethasone Inobrodib Pomalidomide | 0 | 1 |
| Enzalutamide + Inobrodib | Enzalutamide Inobrodib | 0 | 1 |
| Inobrodib | Inobrodib | 0 | 2 |
| Inobrodib + Olaparib | Inobrodib Olaparib | 0 | 1 |